Origin Agritech (SEED) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
22 May, 2026Executive summary
Midpoint of recovery phase in a three-stage plan, focusing on converting rebuilt foundations into commercial and scientific outcomes, with tangible progress in R&D, sales infrastructure, and operational execution.
Net revenue for H1 FY2026 was RMB 49.2 million ($7.1 million), down from RMB 72.3 million year-over-year, reflecting a strategic shift toward new corn seed products and reduced external seed tolling services.
Net loss attributable to shareholders narrowed to RMB 14.4 million ($2.1 million) from RMB 25.6 million a year ago, mainly due to lower general and administrative expenses.
Leadership strengthened with new board and executive appointments, and direct equity investment by CEO.
Financial highlights
Total revenues for H1 FY2026 were RMB 49.2 million ($7.1 million), down 31.9% year-over-year due to strategic product portfolio transition.
Gross profit was RMB 5.5 million ($0.8 million), compared to RMB 8.1 million in the prior year period.
Operating expenses dropped 44% to RMB 18.4 million, driven by a 70% reduction in G&A costs.
Selling and marketing expenses increased 93% to RMB 5.1 million, reflecting intentional investment in commercial campaigns and sales personnel.
R&D expenses rose 11% to RMB 5.7 million, supporting Hi3 platform, gene editing, and proprietary product development.
Outlook and guidance
Operating leverage is becoming visible, with reduced costs and stable gross margin positioning for growth.
Strategic focus remains on expanding new corn seed product sales and reducing lower-margin external seed tolling.
Commercial cycle ahead is concrete, with spring planting and Aoyu 2026 program underway.
First half of FY2027 expected to demonstrate conversion of restructuring efforts into commercial outcomes.
Latest events from Origin Agritech
- Driving China's agricultural modernization with gene-edited, high-yield GMO corn and NEC products.SEED
Corporate presentation25 May 2026 - Revenue fell 90% in 2025, but strategic moves and financing support future growth.SEED
Q4 20252 Feb 2026 - Biotech seed firm with VIE structure plans $30M shelf offering amid regulatory and financial risks.SEED
Registration Filing2 Feb 2026 - Biotech seed firm targets $30M raise amid regulatory shifts and ongoing financial volatility.SEED
Registration Filing2 Feb 2026 - Biotech seed firm targets $30M raise amid regulatory, VIE, and financial risks in China.SEED
Registration Filing2 Feb 2026